Cholangiociliopathies: Genetics, molecular mechanisms and potential therapies

Current Opinion in Gastroenterology

Volumn 25, Issue 3, 2009, Pages 265-271

  Masyuk, Tatyana ^a   Masyuk, Anatoliy ^a   LaRusso, Nicholas ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cholangiociliopathies; Fluid secretion; Hepatic cystogenesis; Proliferation

Indexed keywords

ANGIOPEPTIN; AQUAPORIN; CYTOKINE; ESTROGEN DERIVATIVE; GROWTH FACTOR; MICRORNA; OCTREOTIDE; PROTEIN TYROSINE PHOSPHATASE; RAPAMYCIN; SOMATOSTATIN DERIVATIVE;

AUTOSOMAL DOMINANT DISORDER; CELL CYCLE PROGRESSION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; GENE EXPRESSION; HUMAN; KIDNEY POLYCYSTIC DISEASE; LIVER POLYCYSTIC DISEASE; MOLECULAR GENETICS; NONHUMAN; PATHOGENESIS; REVIEW;

ANIMALS; BILE DUCT DISEASES; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETIC MARKERS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RNA;

EID: 67651101020     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e328328f4ff     Document Type: Review

References (47)

1. Masyuk AI, Masyuk TV, LaRusso NF. Cholangiocyte primary cilia in liver health and disease. Dev Dyn 2008; 237:2007-2012. Functions and role of cholangiocyte cilia in normal and pathological conditions.
2. Adams M, Smith UM, Logan CV, Johnson CA. Recent advances in the molecular pathology, cell biology and genetics of ciliopathies. J Med Genet 2008; 45:257-267. Role of cilia in development of ciliopathies. (Pubitemid 351685144)
3. Pan J. Cilia and ciliopathies: from Chlamydomonas and beyond. Sci China C Life Sci 2008; 51:479-486. Overview of various cilia-related disorders.
4. Hoevenaren IA, Wester R, Schrier RW, et al. Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. Liver Int 2008; 28:264-270. Clinical features in ARPKD and ADPLD. (Pubitemid 351201040)
5. Everson GT, Taylor MR, Doctor RB. Polycystic disease of the liver. Hepatology 2004; 40:774-782.
6. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369:1287-1301. (Pubitemid 46552051)
7. Waanders E, Lameris AL, Op den Camp HJ, et al. Hepatocystin is not secreted in cyst fluid of hepatocystin mutant polycystic liver patients. J Proteome Res 2008; 7:2490-2495. ADPLD protein, hepatocystin, is lost from cystic fluid.
8. Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med 2008 [Epub ahead of print]. Heterogeneity of PKD, animal models, therapies.
9. Ong AC, Harris PC. Molecular pathogenesis of ADPKD: the polycystin complex gets complex. Kidney Int 2005; 67:1234-1247.
10. Ward CJ, Hogan MC, Rossetti S, et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet 2002; 30:259-269. (Pubitemid 34887683)
11. Adeva M, El-Youssef M, Rossetti S, et al. Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore) 2006; 85:1-21. (Pubitemid 43884283)
12. Al-Bhalal L, Akhtar M. Molecular basis of autosomal recessive polycystic kidney disease (ARPKD). Adv Anat Pathol 2008; 15:54-58. Molecular basis of hepatic and renal cystogenesis in ARPKD. (Pubitemid 351627654)
13. Menezes LF, Onuchic LF. Molecular and cellular pathogenesis of autosomal recessive polycystic kidney disease. Braz J Med Biol Res 2006; 39:1537-1548. (Pubitemid 46357839)
14. Bergmann C, Kupper F, Schmitt CP, et al. Multiexon deletions of the PKHD1 gene cause autosomal recessive polycystic kidney disease (ARPKD). J Med Genet 2005; 42:e63.
15. Gallagher AR, Esquivel EL, Briere TS, et al. Biliary and pancreatic dysgenesis in mice harboring a mutation in Pkhd1. Am J Pathol 2008; 172:417-429. Disruption of exon 4 of Pkhd1 results in biliary cystogenesis.
16. Williams SS, Cobo-Stark P, James LR, et al. Kidney cysts, pancreatic cysts, and biliary disease in a mouse model of autosomal recessive polycystic kidney disease. Pediatr Nephrol 2008; 23:733-741. Disruption of exons 1-3 of Pkhd1 results in renal and biliary phenotype.
17. Bisceglia M, Galliani CA, Senger C, et al. Renal cystic diseases: a review. Adv Anat Pathol 2006; 13:26-56.
18. Dawe HR, Smith UM, Cullinane AR, et al. The Meckel-Gruber syndrome proteins MKS1 and meckelin interact and are required for primary cilium formation. Hum Mol Genet 2007; 16:173-186.
19. Klysik M. Ciliary syndromes and treatment. Pathol Res Pract 2008; 204:77-88. Liver disorder in different ciliopathies.
20. Salomon R, Saunier S, Niaudet P. Nephronophthisis. Pediatr Nephrol 2008 [Epub ahead of print]. Genetics and clinical features in NPHP.
21. Hildebrandt F, Otto E. Cilia and centrosomes: a unifying pathogenic concept for cystic kidney disease? Nat Rev Genet 2005; 6:928-940.
22. Kim J, Krishnaswami SR, Gleeson JG. CEP290 interacts with the centriolar satellite component PCM-1 and is required for Rab8 localization to the primary cilium. Hum Mol Genet 2008; 17:3796-3805. CEP290, protein that causes MKS and JBST, is required for ciliogenesis.
23. Harris PC, Torres VE. Understanding pathogenic mechanisms in polycystic kidney disease provides clues for therapy. Curr Opin Nephrol Hypertens 2006; 15:456-463.
24. Brancati F, Travaglini L, Zablocka D, et al. RPGRIP1L mutations are mainly associated with the cerebello-renal phenotype of Joubert syndrome-related disorders. Clin Genet 2008; 74:164-170. Molecular basis of JBTS. (Pubitemid 351974277)
25. Masyuk T, LaRusso N. Polycystic liver disease: new insights into disease pathogenesis. Hepatology 2006; 43:906-908. (Pubitemid 43724613)
26. Alvaro D, Onori P, Alpini G, et al. Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease. Am J Pathol 2008; 172:321-332. Cholangiocyte cilia are abnormal in cystic epithelia of ADPKD patients. (Pubitemid 351282020)
27. Amura CR, Brodsky KS, Gitomer B, et al. CXCR2 agonists in ADPKD liver cyst fluids promote cell proliferation. Am J Physiol Cell Physiol 2008; 294:C786-C796. Agonists of CXCR2 promote cholangiocyte proliferation.
28. Waanders E, Van Krieken JH, Lameris AL, Drenth JP. Disrupted cell adhesion but not proliferation mediates cyst formation in polycystic liver disease. Mod Pathol 2008; 21:1293-1302. Cell adhesion appears to play a major role in hepatic cystogenesis in ADPLD.
29. Banales JM, Masyuk TV, Bogert PS, et al. Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. Am J Pathol 2008; 173:1637-1646. Overexpression of ion transporters and water channels is involved in hepatic cystogenesis.
30. Johnson CA, Gissen P, Sergi C. Molecular pathology and genetics of congenital hepatorenal fibrocystic syndromes. J Med Genet 2003; 40:311-319. (Pubitemid 36613466)
31. Sato Y, Harada K, Ozaki S, et al. Cholangiocytes with mesenchymal features contribute to progressive hepatic fibrosis of the polycystic kidney rat. Am J Pathol 2007; 171:1859-1871.
32. Omenetti A, Porrello A, Jung Y, et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest 2008; 118:3331-3342. Hedgehog signaling may contribute to epithelial-mesenchymal cholangiocyte transition.
33. Karlsson-Rosenthal C, Millar JB. Cdc25: mechanisms of checkpoint inhibition and recovery. Trends Cell Biol 2006; 16:285-292. (Pubitemid 43868088)
34. Lee SO, Masyuk T, Splinter P, et al. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest 2008; 118:3714-3724. Novel mechanism of hepatic cystogenesis that involved microRNAs.
35. Chu AS, Friedman JR. A role for microRNA in cystic liver and kidney diseases. J Clin Invest 2008; 118:3585-3587. Many miRNAs may participate in pathogenesis of liver and kidney cyst development.
36. Masyuk AI, Masyuk TV, Splinter PL, et al. Cholangiocyte cilia detect changes in luminal fluid flow and transmit them into intracellular Ca2+ and cAMP signaling. Gastroenterology 2006; 131:911-920.
37. Gradilone SA, Masyuk AI, Splinter PL, et al. Cholangiocyte cilia express TRPV4 and detect changes in luminal tonicity inducing bicarbonate secretion. Proc Natl Acad Sci U S A 2007; 104:19138-19143.
38. Masyuk AI, Gradilone SA, Banales JM, et al. Cholangiocyte primary cilia are chemosensory organelles that detect biliary nucleotides via P2Y12 purinergic receptors. Am J Physiol Gastrointest Liver Physiol 2008; 295:G725-G734. Cholangiocyte cilia function as a chemosensor.
39. Fischer E, Gresh L, Reimann A, Pontoglio M. Cystic kidney diseases: learning from animal models. Nephrol Dial Transplant 2004; 19:2700-2702. (Pubitemid 39480960)
40. Muchatuta MN, Gattone VH, Witzmann FA, Blazer-Yost BL. Structural and functional analyses of liver cysts from the BALB/c-cpk mouse model of polycystic kidney disease. Exp Biol Med (Maywood) 2008; 234:17-27. Cystic cholangiocyte cilia are abnormal in animal model of PCLD.
41. Alvaro D, Mancino MG. New insights on the molecular and cell biology of human cholangiopathies. Mol Aspects Med 2008; 29:50-57. Cholangiocyte disorder in PCLD.
42. Chang MY, Ong AC. Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and treatment. Nephron Physiol 2008; 108:1-7. Recent advances in the development of PKD therapies.
43. Torres VE, Harris PC. Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities. J Intern Med 2007; 261:17-31.
44. Edelstein CL. Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease. Clin J Am Soc Nephrol 2008; 3:1219-1226. Therapies of PKD.
45. Masyuk TV, Masyuk AI, Torres VE, et al. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 30,50-cyclic monophosphate. Gastroenterology 2007; 132:1104-1116.
46. van Keimpema L, de Man RA, Drenth JP. Somatostatin analogues reduce liver volume in polycystic liver disease. Gut 2008; 57:1338-1339. Octreotide is a potential therapeutic agent for the treatment of hepatic cystogenesis.
47. Qian Q, Du H, King BF, et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 2008; 19:631-638. Sirolimus treatment is associated with reduced liver volumes in patients with PCLD. (Pubitemid 351355407)